EUVIMEDOpdag EUVIMED
Open access

Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531

Erin K Barr, Arlene Naranjo, Clare J Twist, Sheena C Tenney, Mary Lou Schmidt, Wendy B London iD, Julie Gastier-Foster, E Stanton Adkins, Peter Mattei, Michael H Handler, Katherine K Matthay iD, Julie R Park and 3 more

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.31089 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2024. Written by Erin K Barr and 14 co-authors. Institution: Department of Pediatrics, Texas Tech University Health Sciences, Lubbock, Texas, USA. Major MEDLINE topics: Neuroblastoma. Cited 2 times so far (Crossref); 27 references. The full text is freely available in PubMed Central. Funded by: St. Baldrick's Foundation, NCI NIH HHS, NCTN Operations Center.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

We previously reported excellent three‐year overall survival (OS) for patients with newly diagnosed intermediate‐risk neuroblastoma treated with a biology‐ and response‐based algorithm on the Children's Oncology Group study ANBL0531. We now present the long‐term follow‐up results.

Methods

All patients who met the age, stage, and tumor biology criteria for intermediate‐risk neuroblastoma were eligible. Treatment was based on prognostic biomarkers and overall response. Event‐free survival (EFS) and OS were estimated by the Kaplan‐Meier method.

Results

The 10‐year EFS and OS for the entire study cohort ( n = 404) were 82.0% (95% confidence interval (CI), 77.2%‐86.9%) and 94.7% (95% CI, 91.8%‐97.5%), respectively. International Neuroblastoma Staging System stage 4 patients ( n = 133) had inferior OS compared with non–stage 4 patients ( n = 271; 10‐year OS: 90.8% [95% CI, 84.5%‐97.0%] vs 96.6% [95% CI, 93.9%‐99.4%], p = .02). Infants with stage 4 tumors with ≥1 unfavorable biological feature ( n = 47) had inferior EFS compared with those with favorable biology ( n = 61; 10‐year EFS: 66.8% [95% CI, 50.4%‐83.3%] vs 86.9% [95% CI, 76.0%‐97.8%], p = .02); OS did not differ (10‐year OS: 84.4% [95% CI, 71.8%‐97.0%] vs 95.0% [95% CI, 87.7%‐100.0%], p = .08). Inferior EFS but not OS was observed among patients with tumors with ( n = 26) versus without ( n = 314) 11q loss of heterozygosity (10‐year EFS: 68.4% [95% CI, 44.5%‐92.2%] vs 83.9% [95% CI, 78.7%‐89.2%], p = .03; 10‐year OS: 88.0% [95% CI, 72.0%‐100.0%] vs 95.7% [95% CI, 92.8%‐98.6%], p = .09).

Conclusions

The ANBL0531 trial treatment algorithm resulted in excellent long‐term survival. More effective treatments are needed for subsets of patients with unfavorable biology tumors.

Subjects

MeSH terms (MEDLINE)

NeuroblastomaHumansMaleFemaleFollow-Up StudiesChild, PreschoolInfantChildSurvival RatePrognosisAdolescentAntineoplastic Combined Chemotherapy ProtocolsInfant, NewbornNeoplasm Staging

Author keywords

Intermediate risklong‐term follow‐upneuroblastomaoutcomes

Authors and institutions

  • Department of Pediatrics, Texas Tech University Health Sciences, Lubbock, Texas, USA.
  • Department of Biostatistics, University of Florida Children's Oncology Group Statistics and Data Center, Gainesville, Florida, USA.
  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pediatrics and Pathology/Immunology, Baylor College of Medicine, Houston, Texas, USA.

ORCID profiles: Wendy B London, Katherine K Matthay, John M Maris, Susan L Cohn

Funding

  • St. Baldrick's Foundation
  • NCI NIH HHS
  • NCTN Operations Center
  • National Cancer Institute

Cite

APA

Barr, E. K., Naranjo, A., Twist, C. J., Tenney, S. C., Schmidt, M. L., London, W. B., Gastier-Foster, J., Adkins, E. S., Mattei, P., Handler, M. H., Matthay, K. K., Park, J. R., Maris, J. M., Desai, A. V., & Cohn, S. L. (2024). Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31089

Vancouver

Barr EK, Naranjo A, Twist CJ, Tenney SC, Schmidt ML, London WB, et al. Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31089

BibTeX
@article{Barr2024,
  author = {Barr, Erin K and Naranjo, Arlene and Twist, Clare J and Tenney, Sheena C and Schmidt, Mary Lou and London, Wendy B and Gastier-Foster, Julie and Adkins, E Stanton and Mattei, Peter and Handler, Michael H and Matthay, Katherine K and Park, Julie R and Maris, John M and Desai, Ami V and Cohn, Susan L},
  title = {Long‐term follow‐up of patients with intermediate‐risk neuroblastoma treated with response‐ and biology‐based therapy: A report from the Children's Oncology Group study ANBL0531},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.31089}
}
Start for free →